Phaseline

Companies › MAXVAX Biotechnology Limited Liability Company

MAXVAX Biotechnology Limited Liability Company: clinical trials, targets and expected readouts

4 active drug programs in 12 registered trials: 5 Phase 1, 4 Phase 2, 3 Phase 3; Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose
Recombinant RSV vaccine
RSVPhase 3Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus InfectionsFeb 2027
Varicella Zoster Virus Envelope Glycoprotein E
Envelope glycoprotein E vaccine antigen
VZGP5, VZVPhase 3Herpes ZosterNov 2027
Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105
Recombinant varicella zoster virus glycoprotein E vaccine with low dose MA105 adjuvant
VZV, VZVAPhase 2Herpes Zoster–
Recombinant Trivalent Subunit Rotavirus Vaccine (Mid dose)
Recombinant rotavirus subunit vaccine with P types; adjuvanted with aluminum hydroxide
ROTVPhase 2Rotavirus Infections–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05621655Recombinant Trivalent Subunit Rotavirus Vaccine (Mid dose)Phase 2Rotavirus InfectionsInfectious diseaseApr 2023
NCT05621655Recombinant Trivalent Subunit Rotavirus Vaccine (Mid dose)Phase 2Rotavirus InfectionsInfectious diseaseApr 2023
NCT05636436Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105Phase 1Herpes ZosterInfectious diseaseMay 2025
NCT05636436Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105Phase 1Herpes ZosterInfectious diseaseMay 2025
NCT05856084Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105Phase 2Herpes ZosterInfectious diseaseSep 2025
NCT05856084Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105Phase 2Herpes ZosterInfectious diseaseSep 2025
NCT06642558Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dosePhase 1Respiratory Syncytial Virus (RSV)Infectious diseaseFeb 2027
NCT06642558Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dosePhase 1Respiratory Syncytial Virus (RSV)Infectious diseaseFeb 2027
NCT07582796Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dosePhase 1Respiratory Syncytial Virus InfectionsInfectious diseaseSep 2027
NCT06447779Varicella Zoster Virus Envelope Glycoprotein EPhase 3Herpes ZosterInfectious diseaseNov 2027
NCT07293065Varicella Zoster Virus Envelope Glycoprotein EPhase 3Herpes ZosterInfectious diseaseDec 2027
NCT07272434Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dosePhase 3Respiratory Syncytial Virus (RSV)Infectious diseaseDec 2028

Targets

VZV (2) RSV (1) VZGP5 (1) ROTV (1) VZVA (1)

Companies with the same targets

Sanofi ModernaTX Green Cross Guangzhou Patronus Biotech AstraZeneca Enanta Pharmaceuticals Shenzhen Shenxin Biotechnology GSK

Companies built like this

Shenzhen Shenxin Biotechnology Aimei Vacin BioPharm (Zhejiang) Biothervax Xiamen Innovax Biotech OsteoRemedies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.